Skip to main content
. 2011 Mar;336(3):652–660. doi: 10.1124/jpet.110.175331

Fig. 5.

Fig. 5.

In vivo antitumor activity of ELR510444. A, dose-dependent antitumor activity was evaluated in the MDA-MB-231 xenograft model with oral dosing of ELR510444 at 3, 6, or 12.5 mg/kg once daily or ABT-751 at 75 mg/kg once daily. B, the plasma compound concentration over time was determined by liquid chromatography-tandem mass spectrometry after a single oral dose of 25 mg/kg.